ChartRow logo
RVMD
$199.70+2.82%
as of close, Nov 4, 2026
☾ AH $199.70 +2.82%
Share this page

RVMD — Revolution Medicines Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in RVMD be worth today? →
RVMD returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$199.70
YTD price return
+150.72%
YTD total return
+150.72%
Market cap
43.2B
Enterprise value
40.2B
Shares outstanding
216.3M
52W low
$57.74
52W high
$224.31
From 52W high
-10.97%
From 52W low
+245.86%
52W range
85%$57.74–$224
Beta
1.39

Volume

Rel volume
1.25×
30D volume
2M
30D $ vol
387M

Insider trading

Insider net 1W
none
Insider net 1M
−$432K
Insider net 3M
−$78.4M
Insider net 1Y
−$140.3M

Form 4 transactions by trade date, as filed; latest on file 2026-10-26.

Fundamentals

Sales (ttm)
197.6M
Sales/share
$0.91
EPS (ttm)
-$9.14
FCF (ttm)
-1.4B
FCF/share
-$6.66
Book value/share
$11.10
Net margin
-946.82%
ROE
-77.89%
ROA
-43.47%
Debt / equity
0.20×
Current ratio
8.36

Growth (CAGR, ttm) · 10Y

Sales
n/a+180.67%+47.11%n/a
Shares
+11.89%+25.44%+24.03%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
n/a+154.17%+18.60%n/a
Book value/share
+34.44%+13.25%+5.09%n/a
Price
+241.25%+107.93%+42.95%n/a
Total return
+241.25%+107.93%+42.95%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-21.8×
Fwd P/E
-33.2×
P/S (ttm)
218.6×
P/B (mrq)
18.0×
EV/Sales (ttm)
203.4×
FCF yield (ttm)
-3.34%
Buyback yield (realized, 1y)
-11.89%
Shareholder yield (realized, 1y)
-11.89%
Buyback yield (cash, ttm)
-3.82%
Shareholder yield (cash, ttm)
-3.82%

Vs own 10Y history

P/S
83rd
P/B
96th

Bar = where today’s multiple sits in RVMD’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+2.82%
5D
+5.82%
1M
-3.36%
3M
+3.23%
YTD
+150.72%
1Y
+240.96%
5Y
+496.83%
1D
+2.82%
5D
+5.82%
1M
-3.36%
3M
+3.23%
YTD
+150.72%
1Y
+240.96%
5Y
+496.83%

Fundamentals#

Revenue

5Y n/m5Y n/mYoY n/m
$197.6M TTM$197.6M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$1.7B TTM−$373.1M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$9.14 TTM−$1.90 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$1.4B TTM−$419.3M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$1.4B, capex −$9.4M

Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow −$415.6M, capex −$3.7M

Shares (diluted)

5Y +246.5%5Y +246.5%YoY +13.6%
204.6M TTM214.9M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m
−$1.9B TTM−$407.5M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full RVMD financials →

About Revolution Medicines#

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.

Redwood City, CA·883 employees·Biotechnology·revmed.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding RVMD#

20 of the 193 ETFs ChartRow carries live hold RVMD. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF2.8%
XBISPDR S&P Biotech ETF1.2%
VBKVanguard Small-Cap Growth ETF1.1%
IWPiShares Russell Mid-Cap Growth ETF1.0%
VHTVanguard Health Care ETF0.5%
VBVanguard Small-Cap ETF0.5%
VXFVanguard Extended Market ETF0.4%
IWRiShares Russell Midcap ETF0.3%
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
NVSNovartis AG+17.01%+3.59%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%